Empagliflozin in Heart Failure with a Preserved Ejection Fraction

In a randomized trial, 5988 patients with heart failure with preserved ejection fraction were assigned to receive either empagliflozin or placebo in addition to usual therapy. At a median of 26 months, the empagliflozin group had a lower incidence of cardiovascular death or hospitalization for heart...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-10, Vol.385 (16), p.1451-1461
Hauptverfasser:	Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Ferreira, João P, Bocchi, Edimar, Böhm, Michael, Brunner–La Rocca, Hans-Peter, Choi, Dong-Ju, Chopra, Vijay, Chuquiure-Valenzuela, Eduardo, Giannetti, Nadia, Gomez-Mesa, Juan Esteban, Janssens, Stefan, Januzzi, James L, Gonzalez-Juanatey, Jose R, Merkely, Bela, Nicholls, Stephen J, Perrone, Sergio V, Piña, Ileana L, Ponikowski, Piotr, Senni, Michele, Sim, David, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Tsutsui, Hiroyuki, Verma, Subodh, Vinereanu, Dragos, Zhang, Jian, Carson, Peter, Lam, Carolyn Su Ping, Marx, Nikolaus, Zeller, Cordula, Sattar, Naveed, Jamal, Waheed, Schnaidt, Sven, Schnee, Janet M, Brueckmann, Martina, Pocock, Stuart J, Zannad, Faiez, Packer, Milton
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antidiabetics Benzhydryl Compounds - administration & dosage Benzhydryl Compounds - adverse effects Cardiology Cardiology and cardiovascular system Cardiology General Cardiovascular diseases Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Chronic Disease Congestive heart failure Diabetes Diabetes mellitus Double-Blind Method Ejection fraction Female Glucosides - administration & dosage Glucosides - adverse effects Heart Failure Heart Failure - drug therapy Heart Failure - physiopathology Hospitalization - statistics & numerical data Human health and pathology Humans Hypotension Life Sciences Male Patient safety Placebos Sodium-glucose cotransporter Sodium-Glucose Transporter 2 Inhibitors - administration & dosage Sodium-Glucose Transporter 2 Inhibitors - adverse effects Statistical analysis Stroke Volume Urinary tract
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a randomized trial, 5988 patients with heart failure with preserved ejection fraction were assigned to receive either empagliflozin or placebo in addition to usual therapy. At a median of 26 months, the empagliflozin group had a lower incidence of cardiovascular death or hospitalization for heart failure than the placebo group.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2107038